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Background:Contraction of cardiomyocytes up-regulates glucose and fatty acid uptake byGLUT4 andCD36 translocation
to the sarcolemma.
Results: Silencing of protein kinase D1 abolishes contraction-induced GLUT4 but not CD36 translocation.
Conclusion: Protein kinase D1 signaling mediates cardiac glucose but not fatty acid uptake.
Significance: Selective stimulation of glucose uptake is beneficial for diabetic hearts characterized by elevated fatty acid uptake.
Increased contraction enhances substrate uptake into car-
diomyocytes via translocation of the glucose transporter GLUT4
and the long chain fatty acid (LCFA) transporter CD36 from intra-
cellular stores to the sarcolemma. Additionally, contraction acti-
vates the signaling enzymes AMP-activated protein kinase
(AMPK)andproteinkinaseD1 (PKD1).AlthoughAMPKhasbeen
implicated in contraction-induced GLUT4 and CD36 transloca-
tion in cardiomyocytes, theprecise role ofPKD1 in theseprocesses
is not known. To study this, we triggered contractions in car-
diomyocytes by electric field stimulation (EFS). First, the role of
PKD1 in GLUT4 and CD36 translocation was defined. In PKD1
siRNA-treated cardiomyocytes as well as cardiomyocytes from
PKD1 knock-out mice, EFS-induced translocation of GLUT4, but
notCD36,wasabolished. InAMPKsiRNA-treatedcardiomyocytes
and cardiomyocytes fromAMPK2 knock-outmice, bothGLUT4
and CD36 translocation were abrogated. Hence, unlike AMPK,
PKD1 is selectively involved in glucose uptake. Second, we ana-
lyzed upstream factors in PKD1 activation. Cardiomyocyte con-
tractions enhanced reactive oxygen species (ROS) production.
Using ROS scavengers, we found that PKD1 signaling and glucose
uptake are more sensitive to changes in intracellular ROS than
AMPKsignalingorLCFAuptake.Furthermore, silencingofdeath-
activated protein kinase (DAPK) abrogated EFS-induced GLUT4
but not CD36 translocation. Finally, possible links between PKD1
and AMPK signaling were investigated. PKD1 silencing did not
affect AMPK activation. Reciprocally, AMPK silencing did not alter
PKD1 activation. In conclusion, we present a novel contraction-in-
duced ROS-DAPK-PKD1 pathway in cardiomyocytes. This pathway
is activated separately from AMPK and mediates GLUT4 transloca-
tion/glucoseuptake, butnotCD36 translocation/LCFAuptake.
Cardiac substrate utilization is predominantly regulated by
GLUT4 and CD36, the main cardiac transporters for glucose
and long chain fatty acids (LCFA),2 respectively (1). In addition
to being present at the sarcolemma, GLUT4 and CD36 are also
stored in endosomal compartments, from where these trans-
porters can be translocated to the sarcolemma. GLUT4 trans-
location is known to be a vesicle-mediated process depending
on, a.o., coat, and SNARE proteins. Recently, both groups of
proteins have also been found to mediate CD36 translocation
(2). Alterations in contraction are an important denominator of
cardiac substrate utilization. Increased contraction enhances
the demands for glucose and LCFA, and accordingly, GLUT4
and CD36 have been found to translocate to the sarcolemma
under this condition (1, 3).
The signaling pathways involved in contraction-induced
GLUT4 and CD36 translocation in the heart have been incom-
pletely charted. Contraction signaling is under control of the
cardiac energy status, and particularly sensitive to increases in
intracellular levels of AMP (4). AMP binds to the regulatory
-subunit of the heterotrimeric enzymeAMP-activated protein
kinase (AMPK). This binding allosterically further stimulates
activity of AMPK phosphorylated at Thr172 within the catalytic
-subunit by the upstream kinase LKB1, and simultaneously
inhibits Thr172 dephosphorylation (4). Both LKB1 and AMPK
have been shown to be necessary for GLUT4 and CD36 trans-
location in cardiomyocytes (5, 6). However, it is not known
whether there are also kinases that are differentially involved in
contraction-induced GLUT4 and CD36 translocation in the
heart.
Another contraction-activated kinase in the heart is protein
kinase D1 (PKD1). Contraction stimulation has recently been
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found to autophosphorylate PKD1 at Ser916, resulting in
increased phosphorylation of established PKD target proteins
(7). PKD1 is the founding member of the PKD family, a novel
family of protein kinase C-related Ser/Thr kinases. PKD1 is
associated with a number of cellular processes. For instance,
PKD1 is involved in translocation of secretory proteins from
the Golgi to the plasma membrane in secretory cells (8). Addi-
tionally, PKD1 links increased production of reactive oxygen
species (ROS) to inflammatory responses through activation of
nuclear factor B (9). Previously, we discovered that PKD1 is
linked to contraction-induced glucose uptake (7). However, the
pharmacological agents used to inhibit PKD additionally inhib-
ited PKCmembers and a variety of other kinases (7). Hence, the
role of PKD1 in contraction-induced GLUT4 translocation
awaits more definite proof. Furthermore, the role of PKD1 in
contraction-induced CD36 translocation is unknown.
In this study, we examined the role of PKD1 in glucose and
LCFA uptake in contracting cardiomyocytes and compared the
effects of PKD1 with those of AMPK in inducing GLUT4 and
CD36 translocation. Furthermore, we mapped the signaling
events upstreamof PKD1, focusing onROSas candidate second
messenger. Finally, we investigated whether or not PKD1 sig-
naling converges with AMPK signaling in regulation of con-
traction-induced substrate uptake in the heart. For manipula-
tion of PKD1 and AMPK expression, we used the cardiac cell
line HL1, in which we knocked down PKD1 and AMPK via
siRNA technology. We also used cardiomyocytes from cardio-
specific PKD1 and AMPK2 knock-out mice. For inhibition
and activation of ROS signaling, we treated primary rat car-
diomyocytes withN-(2-mercaptopropionyl)glycine (MPG) and
H2O2, respectively. We conclude that upon contraction-in-
duced ROS production, PKD1 becomes activated and induces
GLUT4, but not CD36 translocation, separately from AMPK.
EXPERIMENTAL PROCEDURES
Animals—Male Lewis rats (200–250 g) were obtained from
Charles River. Mice with a conditioned PKD1-null allele were
generously provided by Prof. E. N. Olson (Dallas, TX) and
cross-bred with transgenic mice with a Cre-recombinase gene
under aMHCpromoter (Fielitz PNAS 2008). Knock-outmice
in which the AMPK2 catalytic subunit gene was inactivated
were derived from one of our laboratories (10). All of the ani-
mals were maintained at the Experimental Animal Facility of
Maastricht University. The investigation conforms to the
Guide for Care andUse of LaboratoryAnimals published by the
United States National Institutes of Health (Publication No.
85-23, revised 1996).
Materials—Lipofectamine 2000, MPG, and 5-(and 6)-car-
boxy-2,7-dichlorodihydrofluorescein diacetate were pur-
chased from Invitrogen. Liberase blendzyme 1, complete pro-
tease inhibitor, and PhosSTOP phosphatase inhibitor were
obtained fromRoche Applied Science. Igepal CA-630 was from
Sigma. siRNAs against PKD1 (GGAGGGUGAUCUCAUU-
GAAtt), AMPK2 catalytic subunit (GCACGGU-
CAAGUUUUGAUUtt), and DAPK1 (GCAAGAAACAU-
UAGCGAAUtt), were obtained from Ambion Applied
Biosystems (Austin, TX). The plasmid coding for GLUT4myc
was kindly provided by Dr. J. Eckel (German Diabetes Center,
Düsseldorf, Germany). GFP eukaryotic expression vector
pEGFP-N1 was from Clontech. Antibodies directed against
phospho-PKD/PKC- (Ser916), phospho-AMPK (Thr172),
GAPDH, caveolin 3, and the Myc epitope were obtained from
Cell Signaling (Beverly, MA), and the antibody directed against
DAP kinase-1 was purchased from Sigma-Aldrich. The anti-
body directed against GLUT4 was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA), and the antibody against
mouse CD36 was from Chemicon (Billerica, MA). Protein
G-Sepharose beads were from GE Healthcare.
Experimental Procedures on HL-1 Atrial Cardiomyocytes—HL-1
cells were kindly provided byDr. Claycomb (Louisiana StateUniver-
sity,NewOrleans, LA) and cultured as previously described (2).HL1
cells were transfected with noncoding (nc)-, PKD1-, AMPK-, or
DAPK1-siRNA and cotransfected with pCMV-GLUT4myc (in case
of sarcolemmalGLUT4detection). Transfection of siRNAwas done
bymixing 200 pmol of siRNAwith 8 l of Lipofectamine 2000/well
(6-wellplate) inantibiotic- andnorepinephrine-freeculturemedium.
After 6h, themediumwas changed to regular culturemedium.After
48 h, the medium was changed to FCS- and norepinephrine-free
mediumovernight. Subsequently, the cells were subjected to electric
field stimulation (EFS) for inducing controlled cellular contractions
(in case of substrate uptake studies and transporter translocation
assays)or subjected tooligomycin treatment (incaseofverificationof
loss of signaling caused by silencing of each of the three kinases). In
case of EFS, theC-Pace stimulator from IonOptix (Milton,MA)was
usedat a settingof 40V, 5-mspulseduration, and2Hz for 30min. In
caseofoligomycin,thecellswereincubatedfor30minat1M.Imme-
diately thereafter, the following parameters were measured: expres-
sion and phosphorylation of PKD1 and AMPK (6, 7); sarcolemmal
contentsofCD36andGLUT4myc;uptakeofglucoseandLCFA;and
microscopical detection of GLUT4 translocation. For detection of
total and phosphorylated PKD1 and AMPK, the cells were lysed in
Laemmli sample buffer and then subjected to immunoblotting (see
below).
In case of sarcolemmal CD36 detection, the cells were incu-
bated with an anti-CD36 antibody (1:2,000 in blocking buffer)
for 30min at room temperature and subsequentlywashed three
times with blocking buffer. Next, the cells were incubated with
a HRP-linked secondary antibody (1:4,000 in blocking buffer)
for 30 min at room temperature. After extensive washing with
blocking buffer and then with PBS, an ortho-phenylenedi-
amine-H2O2 solution was added as a substrate for the bound
HRP. The reaction was carried out at room temperature and
stopped after 30min by the addition of 1 MH2SO4. Color devel-
opment, representative of the amount of CD36 present at the
plasma membrane, was quantified by measurement of the
absorbance at 490 nm. The background signal of the control
(incubationwithout primary antibody)was subtracted from the
raw data. In case of sarcolemmal GLUT4myc detection, HL1
cells were cotransfected with a plasmid coding for GLUT4myc
(11) simultaneously with the transfection with the selected
siRNAs. The staining of plasmalemmal GLUT4myc is done
with a primary antibody against Myc and an appropriate HRP-
linked secondary antibody. Furthermore, the GLUT4myc sur-
face staining is homologous to the method of CD36 cell surface
staining.
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For measurement of substrate uptake, palmitate (coupled to
BSA in a palmitate:BSA ratio of 1:3) and deoxy-D-glucose were
added to final concentrations of 20 and 4 M, respectively, with
tracer amounts of [14C]palmitate and 2-deoxy-D-[3H]glucose.
After 10 min, uptake was terminated, and unbound substrate
was removed by washing the cells with ice-cold depletion
medium containing 0.2mMphloretin. After transfer of the glass
slides into new culture dishes, the cells were lysed by the addi-
tion of 1 M NaOH. Subsequently, incorporated glucose and
palmitate were measured by scintillation counting of 14C and
3H.
To microscopically track GLUT4 translocation, murine
GLUT4 cDNA was ligated into pEGFP-N1. The resulting plas-
mid was transfected into HL1 cells using Lipofectamine 2000.
Transfected cells were observed and photographed by a Leica
TCS SPE confocal scanning microscope.
Isolation and Treatment of Adult Rat and Mouse
Cardiomyocytes—Cardiomyocytes were isolated from male
Lewis rats (200–250 g) (12) or from male and female WT or
transgenicC57BL/6mice (6) using a Langendorff perfusion sys-
tem and a Krebs Henseleit bicarbonate medium equilibrated
with a 95% O2, 5% CO2 gas phase at 37 °C. Cardiomyocytes
were incubated at 37 °C with continuous shaking. Rat car-
diomyocytes were subjected to EFS at 40 V, 5-ms pulse dura-
tion, 4 Hz for 6 min. Mouse cardiomyocytes underwent EFS at
40 V, 10 ms, 2 Hz for 4 min. Furthermore, rat or mouse car-
diomyocytes were incubated for 15 min at 37 °C with 5 or 1 M
oligomycin, respectively. For EFS, a IonOptix stimulator was
used. In case of addition of pharmacological inhibitors, com-
pounds were added 30 min prior to stimulation. Immediately
after stimulation, a mixture of [3H]deoxyglucose and
[14C]palmitate was added, and uptake of these substrates was
determined during 5min as pellettable radioactivity in a similar
manner as described for HL1 cells, with the difference that the
cells were washed by low speed centrifugation followed by lysis
directly in scintillation fluid.
Immunoprecipitation—Cardiomyocytes were pelleted and
incubated for 1 h in ice-cold lysis buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1% Igepal CA-630, 0.5% sodium deoxy-
cholate, 0.1% SDS, complete protease inhibitor, and PhosSTOP
phosphatase inhibitor). Cell lysates were pelleted, and the
supernatant fractions were incubated with antibody (5 g)
overnight at 4 °C. 50 l of protein G-Sepharose beads was
added, and incubations were continued for 1 h at 4 °C. The
beads were collected by pulse centrifugation and washed. The
final pellet was resuspended in 30 l of Laemmli sample buffer
and heated to 95 °C for 5 min. The beads were pelleted by cen-
trifugation, and the supernatant was used for Western blot
analysis.
Immunoblotting—Proteins were separated by SDS-PAGE on
4–12% Bis-Tris Criterion XT precast gels (Bio-Rad) and trans-
ferred to nitrocellulose membranes. The membranes were
probed with the relevant primary antibodies according to the
manufacturer’s instructions. The protein bands were visualized
using enhanced chemiluminescence, and immunoblot intensi-
ties were quantitatively analyzed using Bio-Rad Quantity One
software (7).
Flow Cytometry Analysis—Cardiomyocytes were incubated
for 30 min with 10 M 5-(and 6)-carboxy-2,7-dichlorodihy-
drofluorescein diacetate. Afterward, the cardiomyocytes were
washed with PBS, and fluorescence was analyzed by flow
cytometry.
Statistics—All of the data are presented as the means  S.E.
Statistical analysis was performed by using Student’s t test or
analysis of variance (including Newman-Keuls multiple com-
parison test) and statistical analysis software Prism 4
(GraphPad Software, Inc.). A p value of 0.05 was considered
statistically significant.
RESULTS
Involvement of PKD1 and AMPK in Contraction-induced
Glucose and LCFA Uptake—HL1 cardiomyocytes were chosen
as model to study the influence of PKD1 and AMPK on cardiac
substrate uptake. This cell line is capable of contracting in an
electric field (2). Additionally, we verified in HL1 cells that
GLUT4 translocation is entirely responsible for stimulus-in-
duced glucose uptake and CD36 translocation for stimulus-
induced LCFA uptake (2). Furthermore, HL1 cells can be read-
ily manipulated with siRNA technology for protein silencing
(2).
Treatment of HL1 cells with siRNA against PKD1 or AMPK
resulted in a 40–50% specific loss of protein expression of each
of these kinases (Fig. 1A). Oligomycin, an inhibitor of mito-
chondrial F1F0-ATPase, has been previously shown to stimu-
late AMPK and PKD activation in a similar manner as does
contraction (3, 7) and was used in these experiments as stimu-
lus to verify whether the down-regulation of synthesis of both
kinases would also reduce their activation. Silencing of PKD1
resulted in a complete loss of oligomycin-induced PKD1-Ser916
phosphorylation, and silencing of AMPK led to a complete loss
of oligomycin-induced AMPK-Thr172 phosphorylation. (Fig.
1A). Furthermore, PKD1 silencing did not affect AMPK activa-
tion, and conversely, AMPK silencing did not influence PKD1
activation, indicating that these kinases operate in separate
pathways (Fig. 1A).
The role of PKD1 in contraction-induced GLUT4 and CD36
translocation was assessed by fluorometric assessment of the
cell surface presence of GLUT4myc and CD36 We observed
that oligomycin treatment and EFS enhanced the sarcolemmal
abundance of both transporters (Fig. 1B). PKD1 silencing abro-
gated the increase in cell surface content of GLUT4, but not of
CD36 (Fig. 1B). In line with these findings, PKD1 silencing
abrogated oligomycin-induced glucose uptake, but not LCFA
uptake, into HL1 cells (Fig. 1B). The involvement of PKD1 in
contraction-induced GLUT4 translocation was visualized
using a GLUT4-GFP hybrid protein. GLUT4-GFP was shown
to be translocated to the sarcolemma upon EFS, and this was
abolished by PKD1 silencing (Fig. 1C).
Contrary to PKD1, AMPK knockdown inHL1 cells inhibited
EFS-induced translocation of both GLUT4 and CD36 (Fig. 1D).
AMPK silencing also caused a modest increase in basal CD36
presence at the sarcolemma.
Given that the knockdowns of both PKD1 and AMPK were
partial (50%), it is of note that the inhibitory effects of these
knockdowns on oligomycin/contraction-induced GLUT4 or
PKD1 and Cardiac Substrate Uptake
FEBRUARY 17, 2012 • VOLUME 287 • NUMBER 8 JOURNAL OF BIOLOGICAL CHEMISTRY 5873
CD36 translocation were total. Both PKD1 and AMPK are
known to be involved in a number of pathways not related to
regulation of substrate uptake (4, 9). Possibly, variations in
thresholds of kinase activity may determine the actual effect of
the down-regulation on each of these pathways.
We also investigated the roles of PKD1 and AMPK in con-
traction-induced glucose and LCFA uptake into primary car-
diomyocytes isolated from cardiospecific PKD1 knock-out
mice and from AMPK2 knock-out mice. We confirmed the
absence of PKD1 andAMPKactivation in cardiomyocytes from
cardiospecific PKD1 knock-out mice and from AMPK2
knock-outmice, respectively (Fig. 2A). In PKD1 knock-out car-
diomyocytes, EFS-inducedAMPK-Thr172 phosphorylationwas
not decreased. Reciprocally, in AMPK2 knock-out car-
diomyocytes, EFS-induced PKD1-Ser916 phosphorylation was
unaltered (Fig. 2A). This latter finding is entirely in line with a
previous study in cardiomyocytes from AMPK2 knock-out
mice, showing that the contraction/oligomycin-induced
increase in enzymatic PKD1 activity was not impaired com-
pared with cardiomyocytes from wild-type littermates (7). EFS
similarly enhanced glucose and LCFA uptake into cardiomyo-
cytes fromwild-type littermates of cardiospecific PKD1 knock-
out mice and AMPK2 knock-out mice (Fig. 2B). EFS-induced
glucose uptake was abolished in both PKD1 knock-out and
AMPK2 knock-out cardiomyocytes (Fig. 2B). EFS-induced
LCFA uptake was abolished in AMPK2 knock-out car-
diomyocytes but was retained in PKD1 knock-out cardiomyo-
cytes (Fig. 2B). Additionally, in PKD1 knock-out cardiomyo-
FIGURE 1. PKD1 silencing in HL1 cardiomyocytes abolishes contraction-induced GLUT4 translocation and glucose uptake but not AMPK activation or
CD36 translocation and LCFA uptake. HL1 cardiomyocytes were transfected with noncoding (nc)-, PKD1-, or AMPK-siRNA (and cotransfected with pCMV-
GLUT4myc in case of sarcolemmal GLUT4 detection). After 48 h, the cells were treated with oligomycin (Oli; 1 M, 30 min) or subjected to EFS for 30 min and
subsequently used for analysis of PKD1 and AMPK signaling, GLUT4 and CD36 translocation, glucose, and LCFA uptake. A, total and phosphorylated PKD and
AMPK were detected by immunoblotting and quantified (n  4). These data confirm that the silencing protocols successfully reduced expression and
activation of each of the kinases. B, PKD1-silenced HL1 cells were used for detection of sarcolemmal GLUT4myc and CD36 contents by a fluorometric assay
following cell staining with an HRP-linked secondary antibody (n  4) and also used for measurement of initial uptake rate of [3H]deoxyglucose and [14C]palmi-
tate (n  4). C, additionally, PKD1-silenced HL1 cells were used for microscopical visualization of GLUT4 translocation. For this, cells were cotransfected with
GLUT4-GFP and after 48 h were subjected to EFS. Translocation of GLUT4-GFP was detected via immunofluorescence microscopy. The nuclei are stained in blue
(DAPI). Only in the nc-siRNA-transfected cells subjected to EFS, did GLUT4-GFP hybrid proteins move out to the plasma membrane. A representative experi-
ment of three is displayed. D, AMPK-silenced HL1 cells were used for detection of sarcolemmal GLUT4myc and CD36 contents as described in B (n  4). *,
statistically different (p  0.05).
PKD1 and Cardiac Substrate Uptake
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cytes, basal LCFA uptake was enhanced (Fig. 2B). Taken
together, PKD1 is specifically involved in GLUT4-mediated
glucose uptake, whereas AMPK is necessary for both GLUT4-
mediated glucose uptake and CD36-mediated LCFA uptake.
Upstream Events of PKD1 in Contraction-induced GLUT4
Translocation and Glucose Uptake—A plausible candidate
kinase directly upstream of PKD1 might be death-activated
protein kinase (DAPK). This kinase has been found to bind to
PKD1 in HEK cells exposed to oxidative stress (13). However,
DAPK has never been linked to cardiac glucose utilization.
Here, we investigated whether in cardiomyocytes DAPK phys-
ically interacts with PKD1 during contraction and whether it
mediates GLUT4 translocation. PKD1 was marginally detecta-
ble in DAPK immunoprecipitates from cardiomyocytes incu-
bated under basal conditions (Fig. 3A). However, DAPK could
be easily detected in PKD1 immunoprecipitates from non-
stimulated cardiomyocytes (Fig. 3A). When cardiomyocytes
were subjected to EFS, there was a large increase in the content
of PKD1 in DAPK immunoprecipitates (Fig. 3A). Reciprocally,
EFS induced the presence of DAPK in PKD1 immunoprecipi-
tates (Fig. 3A). Hence, there is a physical interaction between
DAPK andPKD1 that is augmented by contraction stimulation.
In the DAPK immunoprecipitates, the increase in PKD1 con-
tent caused by EFS is accompanied by a corresponding increase
in Ser916-phosphorylated PKD1 (Fig. 3A), suggesting that bind-
ing of DAPK to PKD1 upon the onset of contraction leads to
PKD1 activation. Knockdown of DAPK (64  7%) abrogated
PKD1 activation (Fig. 3B), EFS-induced GLUT4 translocation
(Fig. 3C), and EFS-induced GLUT4-GFP translocation (Fig.
3D). In contrast, CD36 translocation was not affected by DAPK
knockdown (Fig. 3C). These data indicate that DAPK is neces-
sary for contraction-induced PKD1 activation and subsequent
selective stimulation of GLUT4-mediated glucose uptake.
Furthermore, we hypothesized that ROS presents an
upstream effector of the PKD1-GLUT4 pathway. In isolated
cardiomyocytes, EFS significantly increased ROS formation, as
FIGURE 2. In cardiomyocytes from cardiospecific PKD1 knock-out mice, contraction-induced glucose uptake is lost and LCFA uptake is retained,
whereas in cardiomyocytes from AMPK2 knock-out mice, both contraction-induced glucose and LCFA uptake are lost. Primary cardiomyocytes from
cardiospecific PKD1 knock-out mice (n  5) and AMPK2 knock-out mice (n  5) and corresponding wild-type littermates (n  5 for both groups) were
subjected to 2-Hz EFS prior to measurement of PKD-Ser916 and AMPK-Thr172 phosphorylation (A) or measurement of initial (5 min) uptake of [3H]deoxyglucose
and [14C]palmitate (B). In A, Western blots from wild-type animals are from littermates from AMPK2 knock-out mice. *, statistically different (p  0.05).
PKD1 and Cardiac Substrate Uptake
FEBRUARY 17, 2012 • VOLUME 287 • NUMBER 8 JOURNAL OF BIOLOGICAL CHEMISTRY 5875
did oligomycin (Fig. 4A). Subsequently, we investigated the
ability of ROS to induce PKD1 activation and glucose uptake
and, for comparison, AMPK activation and LCFA uptake.
Indeed, H2O2-induced ROS formation in cardiomyocytes sub-
stantially enhanced PKD1-Ser916 phosphorylation as well as
AMPK-Thr172 phosphorylation (Fig. 4B). H2O2 treatment also
enhanced both glucose and LCFA uptake (Fig. 4C). To investi-
gate whether PKD1 and AMPK are involved in these stimula-
tory actions of H2O2 on substrate uptake, we used the stauro-
sporin-derivative Ro318220, which has been routinely used to
inhibit PKD activation (14) and also adenine 9--D-arabino-
furanoside (ara-A), an established AMPK inhibitor (15). We
confirmed that Ro318220 blocked PKD1 but not AMPK activa-
tion and that ara-A blocked AMPK activation but not PKD1
activation (supplemental Figs. S1A and S2). H2O2-induced glu-
cose uptake, but not H2O2-induced LCFA uptake, was blunted
by Ro318220, whereas both H2O2-induced glucose and LCFA
uptake were blocked by ara-A treatment (Fig. 4C). This pattern
of inhibition of H2O2-induced substrate uptake by Ro318220
and ara-A closely resembled that of oligomycin/EFS-induced
glucose and LCFA uptake into cardiomyocytes (supplemental
Fig. S1B), suggesting a common mechanism. To obtain kinetic
evidence whether H2O2 treatment uses the same mechanisms
as oligomycin or EFS to enhance substrate uptake into car-
FIGURE 3. DAPK is involved in PKD1 activation and contraction-induced GLUT4 translocation. A, primary rat cardiomyocytes were treated with or without
EFS and subsequently used for immunoprecipitation (IP) with monoclonal anti-DAPK or PKD1 antibodies, after which both the DAPK immunoprecipitate and
the PKD1 immunoprecipitate were used for immunoblotting (IB) against total PKD1 protein expression, phospho-PKD-Ser916, and total DAPK protein expres-
sion. In a control immunoprecipitation of cardiomyocytes lysates with a Myc tag antibody, the endogenous c-Myc protein (65 kDa) was successfully immuno-
precipitated, whereas there was no detectable coimmunoprecipitation of DAPK and PKD1. Representative blots are shown (n  3). B and C, HL1 cardiomyo-
cytes were transfected with nc- or DAPK-siRNA and cotransfected with pCMV-GLUT4myc (in case of sarcolemmal GLUT4 detection) and after 48 h were treated
with oligomycin (Oli; 1 M, 30 min) or subjected to EFS. In B, DAPK expression and PKD1-Ser916 phosphorylation were detected by IB (n  4), and in C,
sarcolemmal GLUT4myc and CD36 content were detected by a fluorometric assay following cell staining with an HRP-linked secondary antibody (n  4). D,
additionally, nc-siRNA-treated or DAPK-silenced cells were cotransfected with GLUT4 GFP and after 48 h were subjected to EFS for immunofluorescence
detection of GLUT4 translocation. The nuclei are stained in blue (DAPI). Only in the nc-siRNA-transfected cells subjected to EFS, GLUT4-GFP hybrid proteins
move out to the plasma membrane. A representative experiment of three is displayed. *, statistically different (p  0.05).
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diomyocytes, we investigated the degree of additivity of H2O2-
induced glucose and LCFA uptake with EFS-induced glucose
and LCFA uptake, respectively. H2O2 treatment and EFS each
enhanced glucose and LCFA uptake into cardiomyocytes, but
their combined action did not further enhance glucose and
LCFA uptake (Fig. 4D). This lack of additivity indicates a com-
mon underlying mechanism.
To demonstrate a direct causal relationship between con-
traction-induced ROS production, PKD1 activation, and glu-
cose uptake, we used the ROS scavengerMPG (16). At 0.15mM,
MPG markedly decreased oligomycin-induced PKD1-Ser916
phosphorylation but did not affect AMPK-Thr172 phosphoryl-
ation (Fig. 5A). However, at 1 mM MPG, both phosphorylation
events were largely reduced (Fig. 5A). Additionally, 0.15 mM
MPG largely blocked oligomycin/EFS-induced glucose uptake
without affecting EFS-induced LCFA uptake, whereas 1 mM
MPG blocked oligomycin/EFS-induced LCFA uptake as well
(Fig. 5B). Hence, ROS is involved in contraction-induced PKD1
andAMPK activation as well as in contraction-induced glucose
and LCFA uptake. However, contraction-induced PKD1 acti-
vation and glucose uptake are more sensitive to decreases in
intracellular ROS concentrations than contraction-induced
AMPK activation and LCFA uptake.
DISCUSSION
This study was aimed at investigating the role of PKD1, in
relation to AMPK, in regulating substrate uptake into contract-
ing cardiomyocytes, and also aimed at elucidating the upstream
FIGURE 4. Similarly to contraction stimulation, H2O2-induced ROS formation activates PKD1 and AMPK and stimulates glucose and LCFA uptake into
primary cardiomyocytes. A and B, primary rat cardiomyocytes were treated with oligomycin (Oli; 5 M; 15 min), 4-Hz EFS, or with the ROS donor H2O2 (10 M;
10 min) prior to measurement of ROS production (n  4) (A), measurement of PKD1-Ser916 and AMPK-Thr172 phosphorylation (n  5) (B), and measurement of
initial (5 min) uptake of [3H]deoxyglucose and [14C]palmitate (n  4) (C and D). In C, cardiomyocytes were preincubated with Ro318220 (Ro, 10 M; 30 min) or
ara-A (Ara, 3 mM; 15 min) prior to H2O2 treatment. In D, cardiomyocytes were simultaneously subjected to EFS and treated with H2O2. *, statistically different
(p  0.05).
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events responsible for contraction-induced PKD1 activation.
The presented results yielded the following novel insights: (i)
PKD1 is specifically involved in contraction-induced glucose
uptake, unlike AMPK, being involved in both contraction-in-
duced glucose and LCFA uptake; (ii) the upstream events in
contraction-induced PKD1 activation may include ROS pro-
duction and binding of PKD1 to DAPK; and (iii) PKD1 and
AMPK are activated via separate contraction-induced path-
ways, but activation of both kinases is necessary for GLUT4
translocation.
PKD1 Is Specifically Involved in Contraction-induced Glu-
cose Uptake—In the present study, we obtained three sets of
data that PKD1 is not involved inCD36 translocation andhence
specifically mediates contraction-induced GLUT4 transloca-
tion: (i) in primary cardiomyocytes from cardiospecific PKD1
knock-outmice, contraction-induced glucose uptake was abol-
ished, whereas contraction-induced LCFA uptake was unim-
paired; (ii) in HL1 cardiomyocytes, PKD1 silencing inhibited
contraction-induced glucose uptake but had no effect on con-
traction-induced LCFA uptake; and (iii) in primary rat car-
diomyocytes pharmacological PKD inhibition inhibited con-
traction-induced glucose uptake but not LCFA uptake
(supplemental Fig. S1). On the other hand, AMPK activation is
involved in bothGLUT4andCD36 translocation in cardiomyo-
cytes. First, in rat cardiomyocytes, AMPK-activating stimuli
induce translocation of both GLUT4 and CD36 (1, 3), and in
cardiomyocytes from dominant-negative AMPK expressing
mice (17), both contraction-induced glucose and LCFA uptake
are abolished (6). Moreover, in the present study, we observed
that in AMPK-silenced HL1 cells and in cardiomyocytes from
FIGURE 5. PKD1 activation and stimulation of glucose uptake into primary cardiomyocytes display a greater sensitivity toward ROS scavenging than
AMPK activation and stimulation of LCFA uptake. Primary rat cardiomyocytes were preincubated in absence or presence of indicated concentrations of the
ROS scavenger MPG (30 min) and subsequently treated with oligomycin (Oli; 5 M; 15 min) or EFS prior to Western detection of PKD-Ser916 and AMPK-Thr172
phosphorylation (n  4) (A) or measurement of initial uptake of [3H]deoxyglucose and [14C]palmitate (n  4) (B). *, statistically different (p  0.05).
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AMPK2 mice, both contraction-induced GLUT4-mediated
glucose uptake and CD36-mediated LCFA uptake were
abolished.
In addition to effects on EFS/oligomycin-induced glucose
and/or LCFAuptake, silencing or knock-out of PKD1orAMPK
can also affect basal substrate uptake. In AMPK-silenced cells,
there is a trend to an increased basal GLUT4 and CD36 trans-
location. This suggests that neutralization ofAMPK leads to the
activation of compensatory mechanisms, which increases both
basal glucose and LCFA. In PKD1 KO cardiomyocytes, the
LCFA uptake rate is higher in both basal and EFS conditions.
The increase in LCFA uptake observed in PKD1 KO car-
diomyocytes suggests that PKD1 is able to inhibit LCFAuptake.
Upstream Events in Contraction-induced PKD1 Activation—In
search of an upstream kinase mediating PKD1 activation in car-
diomyocytesandsubsequentGLUT4translocation,wespeculatedon
the involvement of DAPK. Namely, DAPK has been shown in HEK
cells to physically interact with and to activate PKD1 in response to
oxidative stress (13). However, DAPK is mainly known as a tumor
suppressor, the expression of which is greatly reduced in various
human malignancies (18, 19). Until now, no metabolic actions have
been assigned toDAPK.We first studiedwhetherDAPKwould also
physically interactwithPKD1 incardiomyocytes.PKD1 ismarginally
present in DAPK immunoprecipitates from nonstimulated car-
diomyocytes, suggesting that the degree of physical interaction
between both proteins under basal conditions is low. However, in
these same cells DAPK is easily detectable in PKD1 immunoprecipi-
tates, for which we do not yet have a plausible explanation. More
importantly, the onset of contraction enhances binding of DAPK to
PKD1incardiomyocytes.Additionally, the increase intotalPKDcon-
tent in DAPK immunoprecipitates upon contraction stimulation is
closely mirrored by an increase in Ser916-autophosphorylated (and
hence activated) PKD in these precipitates. This implicates that
DAPK-PKD1 binding and PKD1 activation are associated events.
Silencing ofDAPK further illustrates its essential role in contraction-
induced PKD1 activation, because oligomycin did not result in auto-
phosphorylation of PKD1 in DAPK-depleted HL1 cells. Hence,
DAPKisneeded forPKD1autophosphorylation.Combinedwith the
contraction-stimulated binding of total and Ser916-phosphorylated
PKD1 to DAPK, this finding indicates that upon contraction DAPK
increases its affinity for nonphosphorylated PKD1 and activates it
uponbinding.ThemechanismofhowDAPKisactivatedbycontrac-
tion is not known. DAPK silencing also abrogated contraction-in-
duced GLUT4 translocation, thereby adding DAPK to the list of
kinases involved in GLUT4 translocation. Thus, not only PKD1
silencing but also silencing of its upstreamkinase resulted in a loss of
contraction-induced GLUT4 translocation. In contrast, DAPK
silencing did not affect contraction-induced CD36 translocation,
which is in line with the noninvolvement of PKD1 herein. Taken
together,wehave unmasked anovelDAPK-PKD1axis that is specif-
ically involved incontraction-inducedGLUT4translocationandglu-
cose uptake.
In search of a second messenger mediating PKD1 activation
and subsequent GLUT4 translocation, we hypothesized that
ROS might be involved. Namely, it has been shown that the
induction of contraction enhances ROS formation in car-
diomyocytes (20) and that ROS scavengers inhibit contraction-
induced glucose uptake (21, 22). Furthermore, PKD1 is known
to be activated by mitochondrial ROS (9). In the present study,
we confirmed that EFS-induced contraction enhances ROS for-
mation in cardiomyocytes. Also, induced ROS formation in
H2O2-treated cardiomyocytes resulted in Ser916 phosphoryla-
tion and activation of PKD1. On the other hand, ROS scaveng-
ingwith relativelymodest concentrationsMPG inhibited PKD1
activation as well as glucose uptake. AMPK has also been
reported to be activated by a rise in intracellular ROS through
AMPK-Thr172 phosphorylation (23). However, only high con-
centrations of MPG (1 mM) provided sufficient scavenging to
block AMPK activation. This shows that although both PKD1
and AMPK are activated by ROS, these kinases differ in their
sensitivity to ROS. Pharmacological inhibition of AMPK
blocked both ROS-induced glucose and LCFA uptake, whereas
inhibition of PKD1 selectively abrogated ROS-induced glucose
uptake. Hence, enhanced ROS formation has similar effects on
signaling and substrate uptake as EFS and oligomycin-induced
contraction, suggesting that ROS is involved in contraction-
induced glucose as well as LCFA uptake. This notion is further
strengthened by the nonadditivity of ROS-induced glucose and
LCFA uptake with contraction-induced glucose and LCFA
uptake.
In conclusion, ROS and DAPK are both upstream factors
mediating PKD1 activation in contracting cardiomyocytes. Elu-
cidation of the molecular mechanism of interplay among ROS,
DAPK, and PKD1 that leads to PKD1 activation is a topic for
further study.
Both PKD1 andAMPKActivation AreNecessary for Contrac-
tion-induced GLUT4 Translocation—Contraction-induced
GLUT4 translocation is abrogated by either PKD1-knock-
down/knock-out or AMPK-knockdown/knock-out. Hence,
both kinases need to be activated forGLUT4 translocation. The
data obtained in this study indicate that PKD1 and AMPK do
not operate in the same signal transduction pathway tomediate
contraction-induced GLUT4 translocation. Rather they act
parallel to each other, in separate pathways. Evidence for this
concept includes: (i) in PKD1-silenced cells or cardiomyocytes
derived from PKD1 knock-out mice, AMPK activation was
unimpaired, and, reciprocally, in AMPK-silenced cells or car-
diomyocytes fromAMPKknock-outs, PKD1 activationwas not
decreased; (ii) pharmacological inhibition of PKD1 activation
did not affect H2O2-induced AMPK activation, because phar-
macological AMPK inhibition did not affect H2O2-induced
PKD1 activation; (iii) upon modest (0.15 mM) MPG treatment,
PKD1 activation was inhibited, whereas AMPK activation was
unimpaired; and (iv) AICAR is an established AMPK activator
that stimulates LCFA uptake but does not alter glucose uptake
(supplemental Fig. S3) or PKD1 phosphorylation (effect of
AICAR on PKD-Ser916 phosphorylation compared with basal:
1.02 0.05;n 4). This inability ofAICAR to stimulate glucose
uptake is in contrast to observations in skeletal muscle (24),
suggesting that similarities in regulation of GLUT4 transloca-
tion exist between heart and muscle.
This combined evidence that both PKD1 and AMPK appear
to be necessary for GLUT4 translocation but operate separately
from each other suggests that contraction-induced GLUT4
translocation requires the combined input of two separate con-
traction-activated pathways, one involving AMPK and its
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upstream activating kinase LKB1 (4, 6), the other involving
PKD1 and its upstream kinase DAPK. These two pathways are
simultaneously activated upon increased contractile activity
through enhanced ATP utilization and oxidative phosphoryla-
tion, resulting in the simultaneous formation of AMP and ROS,
the secondmessengers for these respective pathways (Fig. 6). In
the present study, we have not investigated intracellular AMP
levels, but earlier we observed a 2-fold increase in intracellular
AMPupon 4-Hz contraction (3, 6). This dual signaling input for
contraction-induced GLUT4 translocation is in line with stud-
ies in skeletal muscle demonstrating that AMPK is essential but
not sufficient for contraction-induced GLUT4 translocation
and glucose uptake (25, 26). On the other hand, another study
in skeletal muscle showed that contraction-induced GLUT4
translocation was found to be dependent on ROS signaling and
independent of AMPK activation (21). Hence, further studies
are needed to study the combined roles of ROS and AMPK
signaling in skeletal muscle.
One can only speculate at which site both contraction-acti-
vated signaling pathways converge to induce GLUT4 translo-
cation. Downstream targets of AMPK signaling are AS160
and/or its closely related family member TBC1D1. Their phos-
phorylation has been shown to relieve GLUT4 from retention
within the recycling endosomes (27). This AMPK signaling-
induced removal of the brake on GLUT4 translocation appar-
ently is not sufficient for initiation of GLUT4 translocation.
Thus, an extra PKD1-dependent input signal is necessary to
induce excision of GLUT4-containing vesicles from the endo-
somal compartment for translocation to the sarcolemma. Then
this raises the question as to how PKD1 signals to endosomes
for induction of GLUT4 translocation. More than 1,000 pro-
teins have been shown to possess a PKD consensus phospho-
rylation motif. Among these proteins are several Golgi-associ-
ated proteins (e.g. diacylglycerol kinase, phosphatidylinositol
4-kinase III, and the acyl transferase CtBP3/BARS), which
function in vesicle-mediated transport between the Golgi and
the plasmamembrane (28). Because theGolgi and the recycling
endosomes are not distinct entities and havemultiplemembra-
nous connections, several of these PKD1 consensus phospho-
rylation motif-possessing proteins of the Golgi could also be
present within the recycling endosomes. One of these proteins
could then be specifically involved in vesicle-mediated trans-
port of GLUT4 from the recycling endosomes to the sarco-
lemma and might cooperate with AS160 to complete the con-
traction-induced excision of GLUT4 vesicles. Such a combined
input of two separate signaling pathways may serve as a control
mechanism to safeguard that GLUT4 translocation will be ini-
tiated under the appropriate metabolic conditions.
In conclusion, in cardiomyocytes, a contraction-activated
ROS-DAPK-PKD1 pathway induces GLUT4 but not CD36
translocation. Selective activation of this pathwaymay shift car-
diac substrate preference toward glucose. Furthermore, selec-
tive stimulation of glucose uptakemight be beneficial for hearts
from type 2 diabetic individuals, which are characterized by
chronically increased LCFA uptake, excessive lipid accumula-
tion, and loss of glucose utilization (1). This selective stimula-
tion of glucose uptake may compensate for the decreased con-
tractile potential of the diabetic heart.
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